SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March:
TD Cowen 45th Annual Health Care Conference
Presenting on Monday, March 3, 2025, at 9:10 a.m. ET
Leerink Partners Global Biopharma Conference
Presenting on Tuesday, March 11, 2025, at 9:20 a.m. ET
Barclays 27th Annual Global Healthcare Conference
Wednesday, March 12, 2025
Jefferies Biotech on the Beach Summit
Wednesday, March 12, 2025
Live webcasts of the TD Cowen 45th Annual Health Care Conference and Leerink Partners Global Biopharma Conference presentations will be accessible on the Investor page of Travere’s website at www.ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact:
Last Trade: | US$25.16 |
Daily Change: | -0.91 -3.49 |
Daily Volume: | 1,565,379 |
Market Cap: | US$2.240B |
September 10, 2025 September 03, 2025 August 27, 2025 June 03, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load